Travere Therapeutics (TVTX) Free Cash Flow Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 24.91% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 20.11% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 14.71% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -10.65% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 31.42% |
| 10 | Travere Therapeutics | 4.34 Bn | 4.26 Bn | 102.38 Mn | 25.92% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 25.92% |
| Dec 31, 2025 | 40.79% |
| Sep 30, 2025 | 29.15% |
| Jun 30, 2025 | 28.77% |
| Mar 31, 2025 | 8.70% |
| Dec 31, 2024 | 31.64% |
| Sep 30, 2024 | -49.48% |
| Jun 30, 2024 | -102.66% |
| Mar 31, 2024 | -56.59% |
| Dec 31, 2023 | -71.16% |
| Sep 30, 2023 | -202.04% |
| Jun 30, 2023 | -97.08% |
| Mar 31, 2023 | -50.09% |
| Dec 31, 2022 | -159.31% |
| Sep 30, 2022 | -85.64% |
| Jun 30, 2022 | -24.44% |
| Mar 31, 2022 | -39.31% |
| Dec 31, 2021 | -214.73% |
| Sep 30, 2021 | 114.57% |
| Jun 30, 2021 | 57.73% |
| Mar 31, 2021 | -27.98% |
| Dec 31, 2020 | -248.29% |
| Sep 30, 2020 | -9.39% |
| Jun 30, 2020 | -48.71% |
| Mar 31, 2020 | -90.53% |
| Dec 31, 2019 | 23.58% |
| Sep 30, 2019 | -72.50% |
| Jun 30, 2019 | -89.36% |
| Mar 31, 2019 | -78.75% |
| Dec 31, 2018 | 7.09% |
| Sep 30, 2018 | -95.67% |
| Jun 30, 2018 | -34.16% |
| Mar 31, 2018 | -30.68% |
| Dec 31, 2017 | 67.88% |
| Sep 30, 2017 | 33.36% |
| Jun 30, 2017 | 34.78% |
| Mar 31, 2017 | 24.77% |
| Dec 31, 2016 | -5.11% |
| Mar 31, 2016 | 7.83% |